How Aging Rewires the Heart and Blood Vessels at the Cellular Level
A 2025 review maps how senescence, inflammation, and mitochondrial dysfunction drive heart failure, arrhythmia, hypertension, and atherosclerosis in aging.
Summary
Aging is the dominant risk factor for cardiovascular disease, and this 2025 review pulls together recent findings on why. It describes how genomic instability, telomere shortening, lost proteostasis, cellular senescence, chronic inflammation, mitochondrial dysfunction, and metabolic shifts remodel the heart and vessels. Specific pathways are linked to individual diseases: myeloid-derived suppressor cells and S100A8/A9 in cardiac fibrosis and HFpEF, Sirt1 and p300 in atrial fibrillation, endothelial senescence via GPR183 in hypertension, and TRAP1, NOX4, and lncRNAs in atherosclerosis. Candidate therapies include metabolic regulators, senolytics, antioxidants, stem cell-derived exosomes, and natural compounds. Most evidence comes from animal and cell models, so clinical translation remains early.
Detailed Summary
Cardiovascular disease is the leading cause of death worldwide, and population aging is a primary driver of its rising burden. This narrative review summarizes roughly five years of research on how aging changes the heart and vasculature, and what that implies for prevention and treatment.
The authors start with general aging biology: telomere attrition, genomic instability, epigenetic change, and loss of proteostasis. They cite work showing that most molecular changes with age are nonlinear (81% nonlinear versus 6.6% linear) and that people with heart disease tend to have shorter telomeres. They then describe age-related structural change. Cardiomyocytes show senescence and hypertrophy, mitochondrial lipid metabolism is impaired, and protease activity declines. Circadian regulation of cardiac electrophysiology is disrupted, and metabolism shifts toward the hexosamine pathway with glycosaminoglycan accumulation. In vessels, Sox9-driven calcification, reduced α1A-adrenoceptor/nNOS–NO signaling, and RGS5-linked pericyte dysfunction promote stiffening and fibrosis.
The review then goes disease by disease. In heart failure, which in aging is mostly HFpEF, granulocytic myeloid-derived suppressor cells promote fibrosis through S100A8/A9 and fibroblast FGF2-SOX9 signaling. Other contributors include loss of miR-146a-5p regulation, Klotho effects on the Nrf2 pathway, and an aged gut microbiome that is reversible by PPARα activation in mice. In atrial fibrillation, age-related fibrosis involves p300, HSPA9/SOD2, and Sirt1-mediated control of necroptosis. In cardiomyopathy, autophagy (Sirt1/PGC-1α/AMPK), BPIFB4, TMEM43 haploinsufficiency, and IL-1 signaling all play roles. In hypertension, fibronectin–integrin α5 signaling, weakened NPRA/PKG/AMPK signaling, GPR183-driven endothelial senescence, and MFAP4 contribute. In atherosclerosis, endothelial and smooth muscle senescence is driven by pathways such as FOXP1/IGF-1/NLRP3, CUX1/p16INK4a, TRAP1-mediated histone lactylation, lncRNA JPX, PPARγ acetylation, and macrophage NOX4-driven mitochondrial dysfunction. The text is truncated before its full treatment of therapies.
The abstract points to metabolic regulators, senolytics, antioxidants, stem cell-derived exosomes, and natural bioactives such as alizarin, IDHP, and dill extract as promising ways to counter these processes. The unifying message is that cardiovascular aging is a multisystem process that can be targeted at several nodes, including senescence, inflammation, mitochondrial function, and metabolism.
Caveats are substantial. This is a narrative review, not a systematic one, and it has no stated search strategy or quality grading. Most mechanisms come from rodents, cell culture, or other animal models, and many are single-study findings. Clinical efficacy of the listed interventions is largely unproven in humans.
Key Findings
- Granulocytic MDSCs accumulate in aging hearts and promote fibrosis via S100A8/A9 and FGF2-SOX9 signaling, a driver of HFpEF.
- Sirt1 limits age-related atrial fibrillation by modulating RIPK1 acetylation and atrial necroptosis; p300 drives atrial fibrosis.
- Endothelial senescence via GPR183 and weakened NPRA/PKG/AMPK signaling link vascular aging to hypertension in aged mice.
- Vascular smooth muscle senescence in atherosclerosis involves TRAP1-driven histone lactylation, lncRNA JPX, and macrophage NOX4 mitochondrial dysfunction.
- Candidate interventions include senolytics, antioxidants, metabolic regulators, stem cell exosomes, and natural compounds, mostly tested only in preclinical models.
Methodology
This is a narrative review of mainly the past five years of literature on cardiovascular aging, covering heart failure, arrhythmia, cardiomyopathy, hypertension, and ischemic heart disease. It has no stated systematic search method, inclusion criteria, or quality appraisal. Evidence is drawn from human cohorts, omics studies, animal models, and cell experiments.
Study Limitations
As a narrative review, it may be subject to selection bias, and most cited mechanisms come from rodent or in vitro studies with uncertain human relevance. Many findings are single studies without replication, and causality is often inferred. The provided text is also truncated, so the therapeutic sections could not be fully assessed.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: